final paragraph from"One final observation. QM nearly got itself into trouble in this case because of its curious publication strategy. It is odd to publish research about the merits of a given set of treatments, without having finalised one’s analytical work on the therapy-specific demerits. From a medical ethics perspective, I wonder to what extent the clinicians and patients appreciated that to some extent the 2011 Lancet publication was work-in-progress – because that is the implication of QM’s arguments on this appeal."
http://ukhumanrightsblog.com/2013/0...-from-a-randomised-controlled-trial-on-mecfs/
JUNE 12, 2013 BY DAVID HART QC
Freedom of information and unpublished data from a randomised controlled trial on ME/CFS